Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study

Table 1

Inclusion criteria for RSV immunoprophylaxis (palivizumab).

Inclusion criteria	Age at the start of RSV season
Gestational age ≤28 weeks	≤12 months
Gestational age ≥29 to <32 weeks	≤6 months
Gestational age ≥32 to <35 weeks	≤6 months and RSV high-risk score of ≥49
Hemodynamically significant CHD, CCF, pulmonary hypertension, etc.	≤6 months
CLD who required medical therapy or required medical treatment within preceding 6 months before starting RSV season	≤24 months
Congenital anomaly of airways or neuromuscular diseases that compromise handling of respiratory secretions	≤24 months
Cystic fibrosis, immunocompromised	≤24 months (case by case basis)

RSV, respiratory syncytial virus; CHD, congenital heart disease; CCF; congestive cardiac failure.